Biomarkers in early-stage non-small-cell lung cancer: Current concepts and future directions

Mauricio Burotto, Anish Thomas, Deepa Subramaniam, Giuseppe Giaccone, Arun Rajan*

*Autor correspondiente de este trabajo

Producción científica: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

50 Citas (Scopus)


Advances in molecular biology and bioinformatics have resulted in the identification of a number of potential biomarkers that could be relevant in the management of patients with non-small-cell lung cancer (NSCLC). Although there is an increasing amount of literature related to these biomarkers, major issues need to be resolved including validity and reproducibility of results. Additionally, in order to interpret the existing literature accurately, a clear distinction must be made between the prognostic and predictive value of biomarkers. The practical applicability of biomarker discovery for patients with lung cancer includes the identification of patients with early-stage NSCLC who are most likely to benefit from adjuvant therapy. Information gleaned from biomarkers has the potential to help in evaluating the role of targeted therapies including immunotherapy in the neoadjuvant and adjuvant setting. The role of gene signatures and the use of newer platforms such as RNA, methylation, and protein signatures is being explored in patients with early-stage NSCLC. This review focuses on the applications of biomarker discovery in patients with early-stage NSCLC.

Idioma originalInglés
Páginas (desde-hasta)1609-1617
Número de páginas9
PublicaciónJournal of Thoracic Oncology
EstadoPublicada - 1 nov. 2014
Publicado de forma externa

Nota bibliográfica

Publisher Copyright:
© 2014 by the International Association for the Study of Lung Cancer.


Profundice en los temas de investigación de 'Biomarkers in early-stage non-small-cell lung cancer: Current concepts and future directions'. En conjunto forman una huella única.

Citar esto